Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma.

ABSTRACT:

Background & aims

The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft safety and rejection have limited its exploration in the neoadjuvant setting of liver transplantation (LT). In this study, we investigate the clinical efficacy and the safety profile of pre-transplant administration of atezolizumab and bevacizumab for HCC.

Methods

Herein, we performed a prospective assessment of 17 patients with HCC treated with neoadjuvant preoperative atezolizumab and bevacizumab prior to LT for HCC, obtained from December 2020 and December 2023 at seven Western transplant centers.

Results

Among the 17 patients with HCC included in the s

SUBMITTER: Tabrizian P 

PROVIDER: S-EPMC11794155 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature